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Background:  The magnitude of which atrial fibrillation independently relates to risk of adverse outcome in patients with asymptomatic aortic 
stenosis (AS) is not well described.
Methods:  Data from clinical examination, electrocardiography (ECG) and echocardiography in 1,873 asymptomatic AS patients randomized to 
simvastatin/ezetimibe combination vs. placebo in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) was used. Atrial fibrillation was Minnesota 
coded and categorized as either paroxysmal or chronic, while aortic valve area and left ventricular (LV) mass was determined by echocardiography 
and indexed by body surface area. Association of atrial fibrillation with risk of adverse outcome was determined by adjusting for age, gender, 
creatinine, cholesterol, blood pressure and echocardiographically estimated aortic valve area and LV mass.
Results:  In multivariable analysis, patients with chronic atrial fibrillation had compared to those without atrial fibrillation, 4.2 times higher risk 
of sudden cardiac death (Risk limits 1.36 - 12.70, p=0.01), 6.3 times higher risk of heart failure due to AS (Risk limits=2.06 - 19.19, p=0.001) 
and 3.8 times higher risk of ischemic stroke (Risk limits=1.45 - 9.83, p=0.007). Adjusted, paroxysmal atrial fibrillation was, compared to no-atrial 
fibrillation, associated with a borderline significant 3.1 times higher risk of heart failure due to AS (Risk limits=0.99 - 9.64, p=0.05) but not of 
ischemic stroke nor cardiovascular death (both p=NS). There was in adjusted analysis, no difference in all cause mortality between patients without- 
vs. paroxysmal- or chronic atrial fibrillation (both p=NS).
Conclusion: In asymptomatic patients with AS, chronic atrial fibrillation was associated with risk of cardiovascular morbidity and mortality 
independent of demographic risks and echocardiographic variables.
